Category Archives: Biotech

Leading Industrial Contractor and Fabricator Wins ABC National Safety Excellence Award

M. Davis and Sons, Inc. has been awarded the National Safety Excellence Award, which is the industry’s leading safety laurel that honors both merit shop general and specialty contractors.

Long Beach, CA, 2018-Mar-30 — /REAL TIME PRESS RELEASE/ — Associated Builders and Contractors Delaware Chapter announced the winners of the prestigious Excellence in Construction award during its 28th annual celebration held in Long Beach, California.

The award was received by the construction and fabrication company M. Davis and Sons received amidst resounding applause.

M. Davis and Sons. Inc. is the leader in construction and fabrication of corporate plants and facilities for Fortune 500 Companies. Their expertise in mechanical, electrical, fabrication, instrumentation, and power distribution equipment create efficient processes for their customers.

Receiving the award has been termed as a milestone for the company as the Excellence in Construction awards program is the industry’s leading competition that honors both general and specialty contractors for innovative and high-quality merit shop construction projects.

Held on March 26, 2018, the ceremony of the ABC’s 28th Annual Excellence in Construction Awards had guests from every corner of the industry.

Talking to them, the 2018 ABC National Chair George R. Nash. Jr., Director of Preconstruction at Branch & Associates in Herndon, VA said,

“I am continually inspired by the amazing talent these ABC members and their employees display every day in the communities they build. It is an honor to recognize their commitment to world-class safety, superior craftsmanship, and cutting-edge innovation. The scope of this year’s Excellence in Construction award-winning projects, from a science museum and luxury apartment buildings to a polyethylene facility and sports stadiums, proves that if it can be built, the merit shop can be built it, on time and on budget.”

The Associated Builders and Contractors (ABC) organizes Excellence in Construction Awards every year and selects winners based on the several criteria such as experience modification rating, OSHA report information, commitment to safe work practices, policy and leadership, and safety vision.

About ABC:
Associated Builders and Contractors (ABC) is a national construction industry trade association established in 1950. It represents more than 21,000 members. Founded on merit shop philosophy, ABC and its 70 chapters help members develop people, win work, and deliver that work safely, ethically, and profitably for the betterment of the communities in which ABC and its members work. For more information visit ABC.org.

About M. Davis & Sons, Inc.
M. Davis & Sons, Inc. is a fifth generation women-owned industrial contractor and fabricator located in Delaware that has served customers for more than 145 years in the oil & gas, chemical, pharmaceutical, food, beverage and industrial markets.

Media Contact:
M. Davis and Sons
Elaine Buonopane
19 Germay Drive
Wilmington, DE
Phone: 302-993-3365
Email: Elaine.Buonopane@mdavisinc.com
www.mdavisinc.com

FINALLY, A REAL INNOVATION IN DENTAL CARE – THE ONLY DUAL MODE LIGHT THERAPY ELECTRIC TOOTHBRUSH LAUNCHES ON KICKSTARTER

Los Angeles, California, 2018-Mar-26 — /REAL TIME PRESS RELEASE/ — Bristl combines proven science of light therapy with sonic vibration to improve oral care. The company also offers a subscription service to replace brush heads, so having the best oral health is also convenient.

Available on Kickstarter on Monday, March 26th at 9am (PST)

The combination of Bristl’s features, convenience, and style make for true market disruption:

Gum Health
Visible Red light (620–750 nm in wavelength) has been clinically proven to heal gum tissue and prevent inflammation. The same technology is often used in skincare; Bristl is bringing it to the everyday tooth brushing routine.

Kill Bacteria
Visible blue light (450–495 nm in wavelength) has been clinically proven to kill and prevent oral bacteria that causes gingivitis and other gum disease. This safe and natural blue light is proven to be effective, and Bristl is proud to bring it to market.

Get Rid of Plaque
Bristl has three sonic vibration modes: regular, gentle, and off. Sonic vibration is recommended by dentists as it has the highest cleaning ability without damaging gums. The brush head is also particularly designed to reach in crack and crevices while letting light pass through the bristles.

A Few Stats
According to a study published in the Journal of Periodontology and Implant Science (Vol. 44: pp. 280-287), Bristl’s technology (even with only red light) was effective in achieving the following:

  • 86% reduction in bacteria that causes destruction of tooth supporting tissue
  • 117% improvement in PPD (Periodontal Pocket Depth) which indicates gum health
  • 80% improvement in CAL (Clinical Attachment Level) which is another metric for gum health

Why Us?
The Bristl Science team consists of a group of innovators and scientists looking to use advanced technology to improve everyday lives. While we of course wish to build a successful business, we are doing so responsibly; Bristl has committed to donating a percentage of every sale to America’s Toothfairy to provide underserved children with dental care. Whether a customer or an underserved child, we’re on a mission to maximize oral health everywhere.

This is just the beginning. The Bristl Science team will work tirelessly to innovate and build products that improve lives, maximize health, and promote good. The Bristl light therapy toothbrush is just the first step toward a healthier future.

Clinical backing, photos, founders quotes, and more information can be found in our Media Kit:
http://bit.ly/2HtKTJ8

Campaign Preview: https://www.kickstarter.com/projects/574806194/565862801?ref=450743&token=dbd4feaa

If you have any questions at all, fee free to give us a call or shoot us an email.

Engineer, Cofounder, Media Contact:

Billy Walker
billy@bristlscience.com
763-607-2889

PEGGY DEL FABBRO, CEO OF M. DAVIS & SONS, APPOINTED TO WOMEN’S ENTERPRISE FORUM LEADERSHIP TEAM

The Women’s Enterprise Forum Serves as a Strategic Advisor to the Women’s Business Enterprise National Council

Wilmington, DE, 2018-Mar-15 — /REAL TIME PRESS RELEASE/ — Peggy Del Fabbro, CEO of M. Davis and Sons, Inc. has been appointed to 2nd Vice Chair of the Women’s Enterprise Forum, which serves on an advisory capacity for the Women’s Business Enterprise National Council (WBENC), the nation’s largest certifier of women-owned businesses and leader in women’s business development.

The Women’s Enterprise Forum provides opportunities for WBENC-Certified Women’s Business Enterprises (WBEs) to represent the voice of all women’s business enterprises and engage in networking and development activities with other WBEs, member corporations and government entities.

As 2nd Vice Chair of the Women’s Enterprise Forum, Peggy will assist in leading the Forum’s primary initiatives to provide input and feedback on WBENC programs and other matters at the direction of the WBENC Board of Directors. A leader in her company and in her community, Peggy values the opportunity to be involved with WBENC at a national level.

To learn more about the Women’s Enterprise Forum, visit http://www.wbenc.org/womens-enterprise-forum/

About WBENC
WBENC is the largest third-party certifier of businesses owned, controlled, and operated by women in the United States. WBENC partners with 14 Regional Partner Organizations (RPOs) to provide its world-class standard of certification to women-owned businesses throughout the country. WBENC is also the nation’s leading advocate of women-owned businesses and entrepreneurs. Throughout the year, WBENC provides business development opportunities for member corporations, government agencies and more than 14,000 certified women-owned businesses at events and other forums. Learn more at www.wbenc.org

About M. Davis & Sons, Inc.
M. Davis & Sons, Inc. is a fifth generation women-owned industrial contractor and fabricator located in Delaware that has served customers for more than 145 years in the oil & gas, chemical, pharmaceutical, food, beverage and industrial markets.

Media Contact:

Elaine Buonopane
M. Davis and Sons, Inc.
19 Germay Drive, Wilmington, DE 19804
Phone Number: 302-993-3365,
Email: elaine.buonopane@mdavisinc.com.
Website: mdavisinc.com

GenQual and R-Pharm collaborate to deliver predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

Seattle, WA, San Francisco, CA and Moscow, Russia, 2016-May-25 — /EPR Network/ — R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases.

The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.

GenQual Founder and CEO Jonathan Mirich said, “This partnership is exciting for GenQual as we advance in our goal to deliver predictive diagnostic tools for the treatment of autoimmune disorders. We are very excited about the possibilities in this space and are thankful to have quality partners in R-Pharm.”

R-Pharm CEO Vasily Ignatiev indicated the importance of the Autoimmune diseases as an area of the development and growth for R-Pharm, as well as the development of novel diagnostic tools aimed to increase the level of predictive response and efficiency of the upcoming treatment paradigm.

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications.  Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level.  GenQual is a privately-held corporation based in Seattle, WA area, USA.

About R-Pharm
R-Pharm is a private Russian pharmaceutical company founded in 2001. It employs over 3,500 highly qualified specialists in 60+ branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA.

The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.

R-Pharm collaborates with major international pharmaceutical companies and universities in the fields of drug discovery, development, clinical trials, manufacturing and commercialization.  The company operates several  GMP compliant manufacturing sites in Russia and Germany, research, BD/licensing and marketing affiliates in Japan, Germany, Turkey and US.

Marketed portfolio and pipeline features drugs used in oncology, hematology, autoimmune diseases, HIV, HCV, neurology, diabetes, cardiology, as well as antibiotics, contrast media and anesthesia agents.

Contact

R-Pharm
info@rpharm.ru
www.r-pharm.com/en/

 

GenQual

info@genqual.com
206.659.7825
www.genqual.com

Creative BioMart Launched Thousands of Assay Kits

Creative BioMart, launched a full list of assay kits to the life science community, aiming to provide its customers with the most comprehensive list of products at reasonable prices.

Shirley, NY, USA (February 4, 2016) — Creative BioMart, a world leader in the manufacturing of research-use protein products and custom protein services, launched a full list of assay kits to the life science community, aiming to provide its customers with the most comprehensive list of products at reasonable prices.

An assay is an investigative procedure in laboratory medicine, pharmacology, environmental biology, as well as molecular biology for qualitatively assessing the presence or amount of a target entity. Assay kits, used in life science research, drug discovery & development, and environmental monitoring, have a wide range of applications such as studying disease pathways, screening for potential drug candidates and evaluating biopharmaceutical production processes.

According to the official speaker in Creative BioMart, this new release of assay kits including over 1600 products such as U2OS C3AR1 Bioassay Kit, eXpress C5AR1 Activated GPCR Internalization Assay, CHO-K1 CCR4 Bioassay Kit, etc.

“By supplying the assay kits to biologists, we hope to further support the scientific research.” commented Linna Green, chief marketing staff in Creative BioMart. “Moreover, this release is just a beginning, we will launch more novel assay kits product in the near future. Customers can get the detailed information on our official website. Hope this launch can help promote our customers’ research and save time for them.”

For more detailed information about Creative BioMart’s newly released assay kits, please visit http://www.creativebiomart.net/product/assay-kits_358.htm or contact 1-631-559-9269.

About Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development. We are offering more than 1,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.

Contact Creative BioMart
Address: 45-16 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-559-9269
Email: info@creative-biomart.com
Website: http://www.creativebiomart.net

Biotage® ACT Plate Adapter Prevents Evaporative Cross-Talk

Biotage® (STO: BIOT), announces the launch of Biotage® ACT (Anti Cross Talk) Plate Adapter, an innovative solution for prevention of well to well cross contamination during extract evaporation.

Uppsala, Sweden — Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the launch of Biotage® ACT (Anti Cross Talk) Plate Adapter, an innovative solution for prevention of well to well cross contamination during extract evaporation.

Biotage® ACT Plate Adapter is an essential accessory for evaporation devices. Constructed from robust, high grade anodized aluminum, it fits on top of the 96-well collection plate containing the sample during evaporation. The plate adapter is compatible with straight needle evaporation devices such as the Biotage® SPE Dry 96 and Biotage® SPE Dry Dual systems, and does not require any changes to the existing analytical method.

The Biotage® ACT Plate Adapter is designed to fit on top of the 96-well collection plate, is reusable and easy to use. Evaporated gases are directed away from the sample wells, eddies are reduced, and the plate adapter reduces the open surface area of the top of the wells, lessening the likelihood that material can re-enter and contaminate adjacent wells.

“During evaporation a proportional amount of analytes present in an extracted sample can contaminate surrounding wells by being carried with the volatilized solvent. If the analyte concentration in one well is considerably higher than the analyte concentration in the surrounding wells it has the potential to cause a clinically significant and erroneous change to the adjacent samples. Biotage® ACT Plate Adapter is the first commercially available device to address the issue of cross talk on evaporation” says Dr. Claire Desbrow, Product Manager, Analytical Chemistry, Biotage.

The plate adapter can be incorporated into existing assays without the need for changing any other aspects of the method, and there is minimal impact of solvent drying times.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 293 employees with sales of 490 MSEK in 2014. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Biotage® Announces EVOLUTE® EXPRESS Columns – Simplified, Fast and Efficient SPE using the Load-Wash-Elute Procedure

Biotage® (STO: BIOT), announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.

Uppsala, Sweden (June 26, 2015) — Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.

EVOLUTE® EXPRESS is a novel family of plates, and now columns, that simplify polymer-based SPE by employing a streamlined three step protocol; Load-Wash-Elute. By using this approach and removing the conditioning and equilibration steps, necessary with traditional bio-analytical SPE procedures, processing and method development times are dramatically reduced without loss of analyte recovery or method robustness.

The EVOLUTE® EXPRESS design provides a uniform flow in the processing of aqueous samples and eliminates the need for re-runs due to clogging. This clear flow technology makes EVOLUTE® EXPRESS particularly efficient and effective when used with SPE automated systems, (such as the Biotage Extrahera™) and enabling consistent, rapid and reliable manual processing.

“Biotage has built a reputation for offering products that simplify Sample Preparation, promoting high throughput and reliability. By expanding the tried and tested EVOLUTE® EXPRESS range we address a real concern for many analysts who have to re-run samples due to well-clogging and sample variability. The minimal three step approach of Load-Wash-Elute considerably improves the way SPE is performed and offers significant time savings for all bio-analysis labs” says Dr. Claire Desbrow, Analytical Chemistry, Product Manager, Biotage.

EVOLUTE® EXPRESS columns are packed with polymer-based EVOLUTE® chemistries (ABN, CX, WCX, AX and WAX) to address most application needs in a wide range of laboratories.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 293 employees with sales of 490 MSEK in 2014. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Broomfield, CO, February 02, 2015 — /REAL TIME PRESS RELEASE/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

MEDIA:

PHOTO:

JPEG

ViroCarb’s anti HIV Crowd Funding Campaign

Toronto, Canada, December 01, 2014 — /REAL TIME PRESS RELEASE NEWS/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.

WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077

Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.

The current treatment of HIV/AIDS involves the use of three or more drugs from five main general classes, used in combination. While this antiretroviral therapy (ART) has helped to reduced morbidity and mortality from AIDS, long term toxicity and the emergence and transmission of drug resistant HIV strains limit the effectiveness. Thus, despite therapy which can render this a chronic, rather than acute fatal infection, development of new drugs to prevent infection and overcome drug resistant strains, is increasingly urgent.

ViroCarb Inc. is developing a novel technology that addresses infections by drug resistant HIV strains. Developed from the identification of a new, natural resistance factor against HIV infection by scientists at SickKids and Canadian Blood Services, ViroCarb’s inhibitor works against a previously overlooked target on the virus to block HIV from entering human cells, the very first step in the infection. It works against all HIV strains.

Funds are needed to aid in moving forward to support preclinical studies; therefore ViroCarb Inc. has started an international crown funding campaign to carry out these HIV model studies needed before conducting clinical trials.
Please support this new way to block HIV.

Contact-Details: Dr. Mario Huesca
479 Simonston Boulevard.
Thornhill ON.
L3T 4M4 Canada

Facebook: https://www.facebook.com/ViroCarb;
Website: http://www.virocarb.com

MEDIA:

VIDEO:

New Biotage® SNAP ULTRA C18 Cartridges – High Performance Reversed Phase Flash Purification

Biotage announces the launch of Biotage® SNAP ULTRA C18 – a range of high performance, reversed phase flash purification cartridges and samplets.

Uppsala, Sweden (November 11, 2014) — Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of Biotage® SNAP ULTRA C18 – a range of high performance, reversed phase flash purification cartridges and samplets.

Biotage® SNAP ULTRA C18 reversed phase cartridges are optimized for use with Biotage ACI™ and Isolera™ flash systems and are available in 12 g, 30 g, 60 g, 120 g, 400 g, 950 g and 1850 g cartridge sizes. They enable chemists to confidently load 2-3% weight percentage of samples onto reversed phase columns, a marked improvement when compared to the currently typical 0.5 – 1% loads. The time taken for purification and solvent usage can therefore be reduced by 50% or a smaller cartridge can be used for the same purification, often with improved purification results.

The new reversed phase cartridges are packed with the new, Biotage® HP-Sphere C18 25 micron spherical silica particles that give a boost to resolution with higher purity peaks over standard reversed phase cartridges. The silica is chemically neutral with no adverse interactions, ensuring higher yields and better recoveries; a wide diversity of purifications are possible, including the use of both acidic or basic modifiers.

“It is no longer enough for suppliers to arbitrarily work on single aspects of the workflow and purification – today a more holistic approach is required, one that involves a combination of factors; with this product range we have further augmented the Biotage ACI™ and Isolera™ flash systems and have created a superior product for purification” says Dr. Sunil Rana, Global Product Manager, Biotage.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 290 employees with sales of 444.6 MSEK in 2013. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.